Stock Report

Download full stock data and analysis for free Last Updated: 15-May-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

Summit Therapeutics Inc. - ADR

Stock Card factsheet share-fund-plan-icon

$18.14

up-down-arrow $-0.65 (-3.46%)

As on 14-May-2026 16:29EDT

Market cap

info icon

$14,483 Mln

Revenue (TTM)

info icon

$0 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

25.7

Div. Yield

info icon

0 %

Summit Therapeutics - ADR Share Price

Compare

High:loading Low:loading Return: loading

Max:loading Min:loading Median:loading

Max:loading Min:loading Median:loading

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 17.79 High: 18.81

52 Week Range

Low: 13.83 High: 30.98

Liquidityliquidity High

Low Moderate High

Fundamentals

  • Net Profit (TTM)Net Profit (TTM) information

    $0 Mln

  • ROEROE information

    -2.7 %

  • ROCEROCE information

    -263 %

  • Industry P/EIndustry P/E information

    --

  • EV/EBITDAEV/EBITDA information

    -5.3

  • Debt to EquityDebt to Equity information

    0

  • Book ValueBook Value information

    $--

  • EPSEPS information

    $-1.2

  • Face valueFace value information

    --

  • Shares outstandingShares outstanding information

    776,162,645

10 Years Aggregate

CFO

£-341.32 Mln

EBITDA

£-348.02 Mln

Net Profit

£-891.55 Mln

Performance

Company
YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Summit Therapeutics - ADR
3.7 -9.4 21.3 -26.3 119.3 27.3 8.1
BSE Sensex*
-11.1 -2.1 -8.9 -7.5 6.6 9.1 11.4
S&P 100#
7.1 10.0 10.9 29.5 24.9 14.7 15.1
As on 14-May-2026  |  *As on 15-May-2026  |  #As on 15-May-2026
Company
2025
2024
2023
2022
2021
2020
2019
Summit Therapeutics - ADR
-2.0 573.1 -38.6 58.0 -42.8 193.8 39.1
S&P 100
18.7 29.0 30.8 -22.1 27.6 19.3 29.5
BSE Sensex
9.1 8.1 18.7 4.4 22.0 15.8 14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details
Quarterly Annual

*All values are in (£ Mln)

Annual

*All values are in (£ Mln)

Annual

*All values are in (£ Mln)

Key Ratios

View Details

5Y Avg -- 3Y Avg -- TTM --

P/E Ratio

--

--Min --Median --Max

P/B Ratio

--

--Min --Median --Max

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

Shareholding Pattern

View Details
These are advertorial stories which keeps Value Research free for all. Click here to mark your interest for an ad-free experience in a paid plan

About Summit Therapeutics - ADR

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific...  antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida. Address: 601 Brickell Key Drive, Miami, FL, United States, 33131  Read more

  • Co-CEO & Executive Chairman

    Mr. Robert W. Duggan

  • Co-CEO & Executive Chairman

    Mr. Robert W. Duggan

  • Headquarters

    Miami, FL

  • Website

    https://www.smmttx.com

Value Research Ratings

Our rating system has guided millions of investors in the past 20 years.

Top Rated Stocks

All stocks with 5-star Value Research Ratings

Top Rated Stocks Icon

High Quality Small Caps

Small-cap stocks rated high on quality score

High Quality Small Caps Icon

High Growth Large Caps

Large-cap stocks with a high growth score

High Growth Large Caps Icon

Value Meets Momentum

Top momentum stocks with a high valuation score

Value Meets Momentum Icon

Top Rated Banks

Banks that rate high on Value Research Stock Ratings

Top Rated Banks Icon
Explore Screeners
Edit peer-selector-edit

FAQs for Summit Therapeutics - ADR

The share price of Summit Therapeutics Inc - ADR is $18.14 (NASDAQ) as of 14-May-2026 16:29 EDT. Summit Therapeutics Inc - ADR has given a return of 119.3% in the last 3 years.

Since, TTM earnings of Summit Therapeutics Inc - ADR is negative, P/E ratio is not available.
The P/B ratio of Summit Therapeutics Inc - ADR is 25.70 times as on 12-May-2026, a 472 premium to its peers’ median range of 4.49 times.


PE & PB ratio at the end of financial year.


Year P/E Ratio P/B Ratio
2025
-12.42
27.41
2024
-74.45
42.37
2024
--
--
2023
-3.79
29.74
2023
--
--

The 52-week high and low of Summit Therapeutics Inc - ADR are Rs 30.98 and Rs 13.83 as of 15-May-2026.

Summit Therapeutics Inc - ADR has a market capitalisation of $ 14,483 Mln as on 12-May-2026. As per SEBI classification, it is a Large Cap company.

Before investing in Summit Therapeutics Inc - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.
Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.